22nd Century Group to launch Pinnacle VLN cigarettes in 1,700 stores

22nd Century Group (XXII) announced an expanded agreement with a top-5 convenience store chain to launch new reduced-nicotine cigarettes and moist snuff products across 1,700 stores in 27 states by late 2025, pending regulatory approvals. This strategic expansion, leveraging the company's proprietary tobacco, aims to drive significant sales growth. While the company reported a Q1 2025 net loss of $3.3 million despite a 50% revenue increase and recently executed a 1-for-23 reverse stock split to maintain NASDAQ compliance, it has reduced operating expenses and targets EBITDA breakeven by late 2025, with analysts projecting sales growth and improved net income.

Analysis

22nd Century Group (XXII) is executing a significant strategic expansion by securing a distribution agreement with a top-5 U.S. convenience store chain for its proprietary reduced-nicotine products. This deal will place its Pinnacle VLN cigarettes, which contain 95% less nicotine, and new moist snuff products into approximately 1,700 stores across 27 states, with a targeted launch in late 2025. This development is the primary driver behind analyst projections for future sales growth. However, the company's financial position presents a mixed picture. While Q1 2025 revenue grew 50% quarter-over-quarter to $6 million, the company still posted a net loss of $3.3 million. To sustain operations and fund this growth, XXII has raised $5.4 million in capital and executed a 1-for-23 reverse stock split to maintain its NASDAQ listing, a move often associated with stocks under pressure. Positively, management has reduced operating expenses to post-turnaround lows and has set a clear target to achieve EBITDA breakeven by late 2025, contingent on continued volume growth and achieving positive gross margins.

Key Decisions for Investors

• Investors should view the expanded distribution agreement as a major potential catalyst for 2025 revenue, but must closely monitor the required state and regulatory approvals, as any delays could significantly impact the timeline and sales projections.
• Despite promising top-line growth, the ongoing net losses, recent dilutive capital raise, and reverse stock split highlight significant financial and execution risks that warrant careful position sizing.
• The company's ability to reach its stated goal of EBITDA breakeven by late 2025 is the most critical metric to watch; achieving this would validate its operational turnaround and growth strategy.